GENE THERAPY FOR USHER SYNDROME
Redefining hereditary blindness : A CERA PARTNERSHIP
Usher Syndrome-
Hereditary Deaf Blindness
The Leading Cause of Hereditary Deaf-Blindness Usher Syndrome is a devastating genetic condition affecting over 400,000 people worldwide.
It is the primary cause of combined hearing and vision loss, often beginning with childhood deafness followed by progressive retinal degeneration that leads to total blindness in early adulthood.
Type 2A, the most prevalent form, accounts for nearly 60% of all cases.
Currently, there is no cure and no treatment—leaving patients to face an inevitable transition into a world of silence and darkness.
Why Gene Therapy is the Only Answer
​
Traditional medicine can manage symptoms, but it cannot stop genetic decay.
To save sight, we must go to the source.
​By correcting the genetic code at the RNA level rather than permanently altering DNA, we offer a safer, reversible, and highly precise solution.
​
​
This isn't just disease management— it is a quest to restore a lifetime of vision
25+ Years of World-Class Research Excellence To solve one of the most complex challenges in medicine, we partnered with the Centre for Eye Research Australia (CERA).
​
Ranked among the world’s elite ophthalmology research institutions, CERA brings:
Scientific Authority
​
Two decades of translating laboratory breakthroughs into life-changing clinical trials.
Cutting-Edge Tech
​
Access to patient-derived retinal organoids ("mini-retinas") and advanced Cas13bt3 RNA editing platforms.
Proven Track Record
​
An unparalleled infrastructure of cellular biology labs and clinical trial networks.
The CERA partnership
Our partnership is developing a potentially curative RNA Base Editing therapy that targets and corrects the USH2A gene mutation.
Image taken by Anna Carlile, courtesy of CERA.
A 50:50 Vision for the Future
​​​
Our Joint Venture represents the pinnacle of Australian innovation. It is a perfect fusion of Clinical Authority and Commercial Mastery:
​
​​CERA provides the world-class research infrastructure and the revolutionary IP behind the RNA editing platform.
MedicVision AI provides the strategic commercial pathway, capital management, and the massive distribution network across the Asia-Pacific.
Together, we are moving through an ambitious roadmap to take this technology from the lab to the patient.
​
By combining CERA’s research excellence with MedicVision’s market access, we are ensuring that the next generation of Usher Syndrome patients will not just dream of a cure—they will have access to one.
Strategic
Milestone
Current Status
​
Proof-of-Concept Validation confirmed in patient-derived models.
Goal
​
Advancing toward IND-enabling studies to bring the first human trials to the Asia-Pacific.